Skip to main content

Featured Content

General Psychiatry
The majority of studies included in a new literature review identified significant improvement in a variety of psychiatric disorders among patients who took hallucinogenic drugs.
A Canadian company has acquired the drug development program for a derivative of ibogaine, a potential treatment for opioid addiction.
It should be the goal of behavioral healthcare executives and practitioners to educate the public and elevate the quality of discourse on basic issues around violent deaths so as to avoid bad policy decisions on mental health and the prevention of violence, writes Ed Jones, PhD.
Major Depressive Disorder
The strongest evidence for the use of nutritional supplements for mental health supports omega-3 as an add-on treatment for major depression, according to a new meta-review.
Child & Adolescent Psychiatry
Gender identity conversion efforts were associated with higher odds of attempted suicide and severe psychological distress in a survey of 27,715 transgender adults, according to a study published online in JAMA Psychiatry.
General Psychiatry
Arshya Vahabzadeh, MD, understands the power neurotechnology can have in the lives of patients. The technology expert recently shared some thoughts on the future of psychiatry, which he will expand upon during his featured session at Psych Congress.
Abuse, PTSD & Trauma
A drug that increases levels of a key endocannabinoid in the brain may be useful for helping patients with post-traumatic stress disorder (PTSD) unlearn fear, suggests an early-stage study published online in Biological Psychiatry.

Meetings & Publications

Back to Top